StocksUS Markets

Securities Fraud Class Action Lawsuits Target UiPath, Shift4 Payments, Masimo Corporation, and Enviva

Bernstein Liebhard LLP, a well-known law firm specializing in investor rights, has alerted investors about important deadlines related to securities fraud class action lawsuits involving UiPath, Inc., Shift4 Payments, Inc., Masimo Corporation, and Enviva, Inc.

The lawsuit concerning UiPath was initiated in the United States District Court for the Southern District of New York. It represents investors who acquired common stock between April 21, 2021, and March 30, 2022. Interested parties wishing to act as lead plaintiffs must submit their motions to the court by November 6, 2023.

A similar lawsuit has been filed against Shift4 Payments in the United States District Court for the Eastern District of Pennsylvania. This case involves investors who purchased securities from November 10, 2021, to April 18, 2023, with the deadline for applying as a lead plaintiff set for October 17, 2023.

Masimo Corporation is also facing legal action with a lawsuit filed in the United States District Court for the Southern District of California on behalf of investors who acquired common stock between February 28, 2023, and July 17, 2023. The deadline for lead plaintiff applications in this case is October 23, 2023.

Additionally, there is a lawsuit against Enviva filed in the United States District Court for the District of Maryland. This lawsuit concerns investors who purchased common stock between November 3, 2022, and May 3, 2023, with a lead plaintiff application deadline of November 13, 2023.

All lawsuits allege violations of the Securities Exchange Act of 1934 against the companies and certain affiliated officers. It is important to note that sharing in any potential recovery does not require serving as a lead plaintiff, and investors who choose not to take any action may remain absent class members.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker